Tribe Capital Growth Corp I

Tribe Capital Growth Corp I is a blank-check company (SPAC) that raised $240M in its initial public offering on Mar 8, 2021, listing on Nasdaq Capital Market. It completed its business combination with Liminatus Pharma, LLC on Apr 30, 2025; the combined company is Liminatus Pharma, Inc. (LIMN). Ellenoff Grossman & Schole advised the SPAC and Graubard Miller advised the underwriters on the IPO.

Liminatus Pharma is a clinical-stage biopharmaceutical company developing cancer therapies that use the body's immune system to recognise and attack cancer cells. It is the target of a proposed business combination with Iris Acquisition Corp.

Status

Merger completed

IPO date

Mar 8, 2021

IPO size

$240M

IPO exchange

Nasdaq Capital Market

Target

Liminatus Pharma, LLC

Announced

Dec 1, 2022

Closed

Apr 30, 2025

Combined company

Liminatus Pharma, Inc. (LIMN)

SPAC counsel (IPO)

Ellenoff Grossman & Schole

Underwriters' counsel (IPO)

Graubard Miller